Subtype
Kidney and Ureter Neoplasm
CI-CAN-00001051Explore in graph →
Non-malignant518 active trials17 approved drugs81 evidence items
- NCIt
- C7514
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001051Explore in graph →
Clinical trials
2,410 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05890781 | Engineering Immune Organoids to Study Pediatric Cancer(IMMUNEORGANOID) | recruiting | N/A | 108 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Feb 9, 2026 | clinicaltrials |
| NCT06349668 | Spinal Morphine or Intravenous Lidocaine in Robot-assisted Upper Urologic Surgery(SMILe) | recruiting | Phase 3 | 220 | Hans BahlmannOTHER | 1 | Feb 5, 2026 |
| NCT07389629 | Iparomlimab and Tuvonralimab (QL1706) Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC | recruiting | Phase 2 | 25 | Sun Yat-sen UniversityOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT07386158 | Pucotenlimab Combination With Vorolanib as Neoadjuvant Therapy for ccRCC | recruiting | Phase 2 | 21 | Sun Yat-sen UniversityOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT02950766 | NeoVax Plus Ipilimumab in Renal Cell Carcinoma | active not recruiting | Phase 1 | 19 | Patrick Ott, MD, PhDOTHER | 1 | Feb 3, 2026 | clinicaltrials |
| NCT04645680 | Diet and Immune Effects Trial: DIET- A Randomized Double Blinded Dietary Intervention Study in Patients With Metastatic Melanoma Receiving Immunotherapy(DIET) | active not recruiting | Phase 2 | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 30, 2026 | clinicaltrials |
| NCT03474497 | UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade | active not recruiting | Phase 1 / Phase 2 | 18 | Megan Daly, MDOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT02432963 | Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy | active not recruiting | Phase 1 | 11 | City of Hope Medical CenterOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT04623502 | An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy | recruiting | N/A | 600 | University of Texas Southwestern Medical CenterOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT06583070 | SABR Combined With Targeted Therapy and Anti-PD-1 for Recurrent or Metastatic Renal Cancer(COSTAR) | recruiting | — | 300 | Peking University First HospitalOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT07369505 | Sapu003 in Advanced mTOR-sensitive Solid Tumors | recruiting | Phase 1 | 27 | SAPU NANO (US) LLCINDUSTRY | 1 | Jan 27, 2026 | clinicaltrials |
| NCT06818136 | Bladder EpiCheck European Haematuria Study | recruiting | — | 800 | Nucleix Ltd.INDUSTRY | 1 | Jan 22, 2026 | clinicaltrials |
| NCT03873402 | A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer | active not recruiting | Phase 3 | 437 | Bristol-Myers SquibbINDUSTRY | 14 | Jan 21, 2026 | clinicaltrials |
| NCT07299357 | Prospective Observational Trial of Image-guided Ablative STereotactic bOdy Radiation Therapy for Primary kidNey Cancer: the STONE Trial | recruiting | — | 53 | Istituto Clinico HumanitasOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT07351266 | Multi-omics Analysis of Renal Cell Carcinoma Mechanisms; Drug Sensitivity Testing in Patient-Derived Cell-based Microtumors | not yet recruiting | — | 10 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Jan 20, 2026 | clinicaltrials |
| NCT02473536 | Neo-adjuvant SABR for IVC Tumor Thrombus in Newly Diagnosed RCC | active not recruiting | Phase 1 / Phase 2 | 25 | University of Texas Southwestern Medical CenterOTHER | 1 | Jan 16, 2026 | clinicaltrials |
| NCT07346404 | Dynamic 82-Rb Positron Emission Tomography (PET) for the Grading of KIDney Carcinoma(RUBIKID) | not yet recruiting | Phase 2 | 50 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jan 16, 2026 | clinicaltrials |
| NCT06234605 | A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma | recruiting | Phase 1 | 80 | HiberCell, Inc.INDUSTRY | 1 | Jan 15, 2026 | clinicaltrials |
| NCT06726421 | Systemic Therapy Alone or With Stereotactic Body Radiotherapy for Oligometastatic Kidney Cancer (STROKER Study)(STROKER) | recruiting | Phase 3 | 252 | Sun Yat-sen UniversityOTHER | 1 | Jan 15, 2026 | clinicaltrials |
| NCT03228667 | QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors | active not recruiting | Phase 2 | 40 | ImmunityBio, Inc.INDUSTRY | 1 | Jan 14, 2026 | clinicaltrials |
| NCT05239533 | Study of Nivolumab in Combination With 177Lu-girentuximab for Kidney Cancer | active not recruiting | Phase 2 | 9 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT04299646 | A Phase II Study Assessing Stereotactic Radiotherapy in Therapeutic Strategy of Oligoprogressive Renal Cell Carcinoma Metastases(GETUG-StORM-01) | recruiting | Phase 2 | 77 | Centre Francois BaclesseOTHER | 1 | Jan 13, 2026 | clinicaltrials |
| NCT07219576 | Retifanlimab and Ruxolitinib In Solid Malignancies(PRISM) | recruiting | Phase 1 / Phase 2 | 40 | University of California, San DiegoOTHER | 1 | Jan 13, 2026 | clinicaltrials |
| NCT07332923 | Predicting HIF-2α Levels in Clear Cell Kidney Cancer Using Machine Learning | active not recruiting | — | 500 | First Affiliated Hospital of Fujian Medical UniversityOTHER | 1 | Jan 12, 2026 | clinicaltrials |
| NCT07324876 | A Multicenter Real-World Study on TKI Therapy After Progression on First-Line TKI/IO Therapy or TKI/IO Therapy After Progression on First-Line TKI in Chinese Patients With Metastatic Renal Cell Carcinoma (mRCC) | not yet recruiting | — | 860 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT07326280 | The Cold Ischemia Robot-assisted Partial Nephrectomy | recruiting | N/A | 310 | Sun Yat-sen UniversityOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT02399124 | Post Marketing Surveillance for PROSENSE™ a Cryotherapy Treatment of Renal Cell Carcinoma(ICE-SECRET) | active not recruiting | N/A | 120 | IceCure Medical Ltd.INDUSTRY | 1 | Jan 6, 2026 | clinicaltrials |
| NCT05544929 | A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers | active not recruiting | Phase 1 | 126 | Novartis PharmaceuticalsINDUSTRY | 12 | Jan 6, 2026 | clinicaltrials |
| NCT06680089 | CD70-targeted immunoPET Imaging of Kidney Cancer | recruiting | Phase 2 | 300 | RenJi HospitalOTHER | 1 | Dec 31, 2025 | clinicaltrials |
| NCT02141919 | Stereotactic Ablative Body Radiation Therapy for Patients With Primary Renal Cancer | active not recruiting | Phase 2 | 16 | University of Texas Southwestern Medical CenterOTHER | 1 | Dec 26, 2025 | clinicaltrials |
| NCT07304492 | AI for Renal Tumors Using Non-Contrast CT | not yet recruiting | — | 10,000 | Fudan UniversityOTHER | 1 | Dec 26, 2025 | clinicaltrials |
| NCT05519878 | Light Therapy and Occupational Therapy Fatigue Management-Based Intervention for Patients With Genitourinary Cancers | recruiting | N/A | 224 | City of Hope Medical CenterOTHER | 1 | Dec 24, 2025 | clinicaltrials |
| NCT07301827 | Study on the Diagnostic Value of Novel PET Molecular Imaging for Renal Cell Carcinoma | recruiting | N/A | 66 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Dec 24, 2025 | clinicaltrials |
| NCT07077447 | The Danish Bladder Cancer Group 23 Study - A European Study on Cancer in the Upper Urinary Tract(EuroCUT) | recruiting | — | 2,500 | Zealand University HospitalOTHER | 2 | Dec 22, 2025 | clinicaltrials |
| NCT07171190 | Targeted Abdominal CT in Conjunction With Lung Cancer Screening(TACTICAL1) | recruiting | N/A | 6,272 | University of CambridgeOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT07294859 | Contrast-enhanced Ultrasound and Super-resolution Imaging Predict Renal Function Outcome After Nephrectomy | recruiting | — | 285 | Jinling Hospital, ChinaOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT05030506 | A Study of Belzutifan (MK-6482) as Monotherapy and in Combination With Lenvatinib (E7080/MK-7902) With or Without Pembrolizumab (MK-3475) in China Participants With Advanced Renal Cell Carcinoma (MK-6482-010) | active not recruiting | Phase 1 | 45 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Dec 18, 2025 | clinicaltrials |
| NCT05856981 | Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors | recruiting | Phase 1 | 130 | Sairopa B.V.INDUSTRY | 3 | Dec 17, 2025 | clinicaltrials |
| NCT06846112 | Randomized Clinical Trial Aimed at Comparing Unclamped Robotic Partial Nephrectomy With or Without Renorrhaphy | active not recruiting | N/A | 248 | Regina Elena Cancer InstituteOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT06210490 | A Clinical Study of the Efficacy and Safety of Disitamab Vedotin in Combination With Radiotherapy for the Adjuvant Treatment of HER2 Overexpressing UTUC Patients With High Risk Factors for Recurrence After Radical Surgery | recruiting | Phase 2 | 60 | Peking University First HospitalOTHER | 1 | Dec 15, 2025 | clinicaltrials |
| NCT07062952 | Kidney-protective Intervention With Salt Substitute After Kidney Tumor Surgery | recruiting | N/A | 200 | Jinling Hospital, ChinaOTHER | 1 | Dec 15, 2025 | clinicaltrials |
| NCT05917106 | Renal Cancer Monitoring Based on ctDNA Methylomics: A Prospective Cohort Study (MEMORY Study) | recruiting | — | 450 | Jinling Hospital, ChinaOTHER | 1 | Dec 11, 2025 | clinicaltrials |
| NCT07277972 | Iparomlimab and Tuvonralimab Injection in Combination With Lenvatinib or Axitinib for the Treatment of Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma That Has Failed First-Line Systemic Therapy | not yet recruiting | Phase 2 | 36 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Dec 11, 2025 | clinicaltrials |
| NCT05363631 | Seleno-L Methionine (SLM)-Axitinib-Pembrolizumab | active not recruiting | Phase 1 / Phase 2 | 55 | Mohammed MilhemOTHER | 1 | Dec 10, 2025 | clinicaltrials |
| NCT05912816 | Combination of DV and Tislelizumab for Renal Preservation in High-risk UTUC Patients | recruiting | Phase 2 | 20 | RenJi HospitalOTHER | 1 | Dec 9, 2025 | clinicaltrials |
| NCT06676527 | Vorolanib in the Second-line Treatment of Patients With Unresectable or Metastatic Renal Cell Carcinoma | recruiting | — | 39 | Jinling Hospital, ChinaOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT06965192 | Designing Visual Tools to Enhance Cancer Surgeon Decision-making | recruiting | N/A | 220 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT07240610 | Abscopal Effect of Ultra-Hypofractionated Radiation Plus Immunotherapy in Metastatic Renal Cell Carcinoma(AURICRE) | recruiting | — | 145 | Zhe ChenOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT04974671 | Trial Of Stereotactic Body Radiation Therapy (SBRT) for Oligoprogression on Immune Checkpoint Inhibitors (ICI) in Metastatic Renal Cell Carcinoma | recruiting | Phase 2 | 30 | Yale UniversityOTHER | 1 | Dec 4, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Feb 9, 2026source: clinicaltrials